Key facts
- Sonomind’s last known valuation is $52.3M (Sep 2025).
- It has raised $3.5M; the latest was Seed Round ($3.5M) in Sep 2025.
- Notable investors include Critical Path Ventures, French Government.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sonomind
- ·The full record, as it builds
Funding rounds
No funding rounds for Sonomind are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sonomind
Developer of non-invasive neuromodulation technology designed for rapid treatment of depression. The company's platform uses ultrasound-based brain stimulation with millimeter precision, customized acoustic meta-lenses, and proprietary software to target deep brain regions, enabling mental health providers to reduce depressive symptoms quickly, improve treatment safety, and offer alternatives to medication-resistant patients.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2024
- Website
- sonomind.com/
- Ownership
- Privately Held (backing)
Sonomind doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonomind shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonomind in its N-PORT filings yet. We sweep new filings monthly.